{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:47:04Z","timestamp":1792640824575,"version":"4.5.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Loss of a previously effective response while still using adequate antidepressant treatment occurs in a relatively high proportion of patients with major depressive disorder (MDD); therefore, there is a need to develop novel effective treatment strategies.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the efficacy and safety of a single subanesthetic dose of esketamine in boosting the efficacy of oral antidepressants for treating fluctuating antidepressant response in MDD.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This single-center, double-blind, midazolam-controlled pilot randomized clinical trial was conducted at Beijing Anding Hospital, Capital Medical University in China. The study enrolled participants aged 18 years and older with fluctuating antidepressant response, defined as patients with MDD experiencing fluctuating symptoms after symptom relief and stabilization. Patient recruitment was conducted from August 2021 to January 2022, and participants were followed-up for 6 weeks. Data were analyzed as intention-to-treat from July to September 2022.<\/jats:p><\/jats:sec>Interventions<\/jats:title>All participants in the esketamine-treated group received intravenous esketamine at 0.2 mg\/kg in 40 minutes. Participants in the midazolam control group received intravenous midazolam at 0.045 mg\/kg in 40 minutes.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was the response rate at 2 weeks, defined as a 50% reduction in Montgomery-\u00c5sberg Depression Rating Scale (MADRS). Secondary outcomes included response rate at 6 weeks, remission rates at 2 and 6 weeks, and change in MADRS and Clinical Global Impression\u2013Severity score from baseline to 6 weeks; remission was defined by a MADRS score of 10 or lower.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 30 patients (median [IQR] age, 28.0 [24.0-40.0] years; 17 [56.7%] female) were randomized, including 15 patients randomized to midazolam and 15 patients randomized to esketamine; 29 patients completed the study. Response rates at 2 weeks were significantly higher in the esketamine-treated group than in the midazolam control group (10 patients [66.7%] vs 1 patient [6.7%]; P<\/jats:italic>\u2009&amp;lt;\u2009.001). Participants treated with esketamine experienced significantly greater reduction in MADRS score from baseline to 2 weeks compared with those treated with midazolam (mean [SD] reduction, 15.7 [1.5] vs 3.1 [1.3]; P<\/jats:italic>\u2009&amp;lt;\u2009.001). No serious adverse events were observed in this trial, and no psychotogenic effects and clinically significant manic symptoms were reported.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This pilot randomized clinical trial found that a single subanesthetic dose of esketamine could boost the efficacy of oral antidepressants in treating fluctuating antidepressant response, with a good safety profile.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>Chinese Clinical Trial Registry Identifier: ChiCTR2100050335<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.28817","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T15:01:23Z","timestamp":1692025283000},"page":"e2328817","source":"Crossref","is-referenced-by-count":10,"title":["Esketamine vs Midazolam in Boosting the Efficacy of Oral Antidepressants for Major Depressive Disorder"],"prefix":"10.1001","volume":"6","author":[{"given":"Chunfeng","family":"Xiao","sequence":"first","affiliation":[{"name":"Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhou","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anning","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuequan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongdong","family":"Hu","sequence":"additional","affiliation":[{"name":"Unit of Psychological Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunying","family":"Zheng","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiying","family":"Deng","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University Clinical Research Institute, Peking University First Hospital, Beijing, China"},{"name":"Key Laboratory of Epidemiology of Major Diseases, Peking University, Ministry of Education"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"key":"zoi230831r1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jad.2022.05.084","article-title":"Prevalence of depressive disorders and associated demographic characteristics in Shandong: an epidemiological investigation.","volume":"311","author":"Cheng","year":"2022","journal-title":"J Affect Disord"},{"issue":"10352","key":"zoi230831r2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0140-6736(22)01012-1","article-title":"Depression in young people.","volume":"400","author":"Thapar","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"zoi230831r3","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States.","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"zoi230831r4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013491.pub2","article-title":"Prognostic models for predicting relapse or recurrence of major depressive disorder in adults.","volume":"5","author":"Moriarty","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"zoi230831r5","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.cpr.2011.09.003","article-title":"Relapse and recurrence prevention in depression: current research and future prospects.","volume":"31","author":"Beshai","year":"2011","journal-title":"Clin Psychol Rev"},{"issue":"8","key":"zoi230831r6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.cpr.2007.02.005","article-title":"Risk for recurrence in depression.","volume":"27","author":"Burcusa","year":"2007","journal-title":"Clin Psychol Rev"},{"issue":"10159","key":"zoi230831r7","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"zoi230831r8","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1001\/jamainternmed.2015.5214","article-title":"Shared decision making for antidepressants in primary care: a cluster randomized trial.","volume":"175","author":"LeBlanc","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"10","key":"zoi230831r9","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1503\/cmaj.071068","article-title":"Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials.","volume":"178","author":"Deshauer","year":"2008","journal-title":"CMAJ"},{"key":"zoi230831r10","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.9058se1c.04gry","article-title":"Major depressive disorder treatment guidelines in America and Europe.","volume":"71","author":"Davidson","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"14","key":"zoi230831r11","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1056\/NEJMoa2106356","article-title":"Maintenance or discontinuation of antidepressants in primary care.","volume":"385","author":"Lewis","year":"2021","journal-title":"N Engl J Med"},{"issue":"69","key":"zoi230831r12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta25690","article-title":"Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT.","volume":"25","author":"Duffy","year":"2021","journal-title":"Health Technol Assess"},{"issue":"2","key":"zoi230831r13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/01.yic.0000199452.16682.b8","article-title":"Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study.","volume":"21","author":"Akerblad","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"zoi230831r14","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jad.2018.10.357","article-title":"Tachyphylaxis in major depressive disorder: A review of the current state of research.","volume":"245","author":"Kinrys","year":"2019","journal-title":"J Affect Disord"},{"issue":"3-4","key":"zoi230831r15","first-page":"24","article-title":"Identification and treatment of antidepressant tachyphylaxis.","volume":"11","author":"Targum","year":"2014","journal-title":"Innov Clin Neurosci"},{"issue":"7","key":"zoi230831r17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40263-014-0171-5","article-title":"Early switching strategies in antidepressant non-responders: current evidence and future research directions.","volume":"28","author":"Kudlow","year":"2014","journal-title":"CNS Drugs"},{"issue":"8","key":"zoi230831r18","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.4088\/JCP.v68n0814","article-title":"How often do SSRIs and other new-generation antidepressants lose their effect during continuation treatment: evidence suggesting the rate of true tachyphylaxis during continuation treatment is low.","volume":"68","author":"Zimmerman","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"1-2","key":"zoi230831r19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jad.2008.07.007","article-title":"Does tachyphylaxis occur after repeated antidepressant exposure in patients with bipolar II major depressive episode?","volume":"115","author":"Amsterdam","year":"2009","journal-title":"J Affect Disord"},{"issue":"6","key":"zoi230831r20","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.4088\/JCP.17f11681","article-title":"Ketamine for depression, 3: does chirality matter?","volume":"78","author":"Andrade","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"zoi230831r21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpsychires.2020.03.020","article-title":"Registered clinical trials investigating ketamine for psychiatric disorders.","volume":"127","author":"Peyrovian","year":"2020","journal-title":"J Psychiatr Res"},{"issue":"13","key":"zoi230831r22","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/npp.2017.94","article-title":"Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression.","volume":"42","author":"Su","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"zoi230831r23","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).","volume":"25","author":"Fava","year":"2020","journal-title":"Mol Psychiatry"},{"issue":"6","key":"zoi230831r24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study.","volume":"80","author":"Singh","year":"2016","journal-title":"Biol Psychiatry"},{"key":"zoi230831r25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.conb.2015.11.001","article-title":"NMDA antagonist treatment of depression.","volume":"36","author":"Williams","year":"2016","journal-title":"Curr Opin Neurobiol"},{"issue":"3","key":"zoi230831r26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms.","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol Rev"},{"key":"zoi230831r27","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.2147\/NDT","article-title":"Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies.","volume":"12","author":"Han","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"zoi230831r28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study.","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry"},{"issue":"1","key":"zoi230831r29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","article-title":"Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA).","volume":"192","author":"Williams","year":"2008","journal-title":"Br J Psychiatry"},{"key":"zoi230831r30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2147\/NDT.S391096","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray plus a newly initiated oral antidepressant in adult patients with treatment-resistant depression: a randomized, double-blind, multicenter, active-controlled study conducted in China and USA.","volume":"19","author":"Chen","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"zoi230831r31","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s12888-021-03538-y","article-title":"Efficacy and safety of fixed doses of intranasal esketamine as an add-on therapy to oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.","volume":"21","author":"Takahashi","year":"2021","journal-title":"BMC Psychiatry"},{"issue":"9","key":"zoi230831r32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011612.pub3","article-title":"Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.","volume":"9","author":"Dean","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"zoi230831r33","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1017\/S0033291715002159","article-title":"Single I.V. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.","volume":"46","author":"Hu","year":"2016","journal-title":"Psychol Med"},{"issue":"6","key":"zoi230831r34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4088\/JCP.v59n0602","article-title":"Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments.","volume":"59","author":"Byrne","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"3-4","key":"zoi230831r35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000288880","article-title":"Do antidepressant and antianxiety drugs increase chronicity in affective disorders?","volume":"61","author":"Fava","year":"1994","journal-title":"Psychother Psychosom"},{"issue":"6436","key":"zoi230831r36","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat8078","article-title":"Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation.","volume":"364","author":"Moda-Sava","year":"2019","journal-title":"Science"},{"key":"zoi230831r16","volume-title":"Stedman\u2019s Medical Dictionary","author":"Nichols","year":"2000","edition":"27th ed"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2808245\/xiao_2023_oi_230831_1691084035.06334.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T15:01:30Z","timestamp":1692025290000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2808245"}},"subtitle":["A Pilot Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.28817","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,14]]}}}